Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

harmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this rele
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Pa. , Sept. 15, 2014 /PRNewswire-iReach/ -- ... -based biotechnology company developing calcium phosphate (CaP)-based nanoparticle ... the company has entered a License Agreement with ... biotechnology company developing immunotherapy products for the treatment ... Under the terms of the agreement, ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 ... one roof Saturday to learn, interact and participate ... York City,s first Lupus Trials Fair launched by ... the S.L.E. Lupus Foundation .  Attendees interacted ... institutions -- sharing experiences, ideas and needs and ...
(Date:9/15/2014)... LINCOLNSHIRE, Ill. , Sept. 15, 2014 /PRNewswire/ ... testing equipment and information systems technology, announced today ... (LABSCO).  This agreement is for Sysmex reagents, controls ... Sysmex pocH-100 i ™ , Sysmex XP-300™, ... The agreement is effective immediately and continues ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3
... July 14 Samsung Medical Center and the world,s leading bio-pharmaceutical company ... research partnership to jointly analyze tumors from Korean patients to generate gene expression ... patients with liver cancer. , , ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SANTA ROSA, Calif. , July 14 ... Santa Rosa, California , today received a notice of ... company which was started in 2006 has thirteen additional patent ... the world for related spinal therapies and devices. The lead ...
Cached Medicine Technology:Pfizer and SMC Collaborate on Liver Cancer 2Pfizer and SMC Collaborate on Liver Cancer 3Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
(Date:9/15/2014)... September 15, 2014 The Best ... World Report consists of seven hospitals using OnBase as ... Hospital and Cleveland Clinic were ranked at the top ... respectively. The rankings cover nearly 5,000 medical centers across ... 17 hospitals that scored highest in at least six ...
(Date:9/15/2014)... 2014 (HealthDay News) -- U.S. heart experts recommend doctors ... when evaluating young people for underlying heart disease that ... Heart Association and the American College of Cardiology said ... and family medical history along with a physical examination ... (existing from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... estimated 8% of Americans will suffer from post traumatic ... Brought on by an overwhelming or stressful event or ... physiology of the brain. Understanding how threat is processed ... is essential to developing effective interventions. , New ... of Texas at Dallas published online today in ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 This year, ... its founding in 2007. To mark the special occasion, ... for supporting the village and helping it to get ... safe, secure and fun community for seniors. Members of ... community and live in their own homes. They are ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Axel Ullrich, Ph.D., is the recipient of the ... his pioneering work in the translation of genomics-based discoveries ... Director of Molecular Biology at the Max Planck Institute ... expert in gene technology and one of the most ...
... of activity helped men, women regardless of family history ... level of aerobic fitness can significantly reduce stroke risk ... study. , The study, expected to be presented Thursday ... New Orleans, showed 30 minutes or more of brisk ...
... connection, experts say , , THURSDAY, Feb. 21 (HealthDay News) ... anywhere else for that matter, may raise your risk ... , "These authors report a potentially important association between ... said Dr. Steven V. Pacia, director of neurology at ...
... similarities, differences in DNA, studies find , , THURSDAY, ... such examination of human genetic diversity yet conducted, an ... to track differences and similarities between people around the ... Science , a team led by Richard Myers, ...
... drugs raises risk of adverse side effects ... take more than one nonsteroidal anti-inflammatory drug (NSAID) may ... suggests. , NSAIDs, which are available in both prescription ... arthritis. , These drugs are widely available, and patients ...
... release is available in Spanish . , ... field of health. However, they are vitally important for patients ... carried out at the Department of Social Anthropology ... lecturer Rafael Briones Gmez, shows that Spanish hospitals are not ...
Cached Medicine News:Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 2Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 3Health News:Moderate Aerobic Fitness Levels May Cut Stroke Risk 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 3Health News:Global Analysis of Human DNA Tracks Migration, Identity 4Health News:Taking Multiple Pain Relievers May Cause Complications 2Health News:Patients' relatives are ignored by the health system and suffer emotional stress 2
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: